Cellectar Biosciences (CLRB) Capital Expenditures Growth (5y) (2016 - 2024)
Cellectar Biosciences (CLRB) Capital Expenditures Growth (5y) (2016 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cellectar Biosciences | 6.73 Mn | 6.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 60.66% |
| Jun 30, 2024 | 17.54% |
| Mar 31, 2024 | 28.22% |
| Dec 31, 2023 | -7.01% |
| Sep 30, 2022 | -23.05% |
| Jun 30, 2022 | -22.52% |
| Mar 31, 2022 | -14.63% |
| Dec 31, 2021 | 14.13% |
| Sep 30, 2021 | 31.05% |
| Dec 31, 2020 | -1.63% |
| Jun 30, 2020 | 33.36% |
| Mar 31, 2020 | -16.15% |
| Dec 31, 2019 | -14.00% |
| Sep 30, 2019 | 6.99% |
| Mar 31, 2019 | -16.30% |
| Dec 31, 2018 | 97.22% |
| Mar 31, 2018 | -56.64% |
| Sep 30, 2017 | 26.76% |
| Jun 30, 2017 | 78.59% |
| Mar 31, 2017 | 34.35% |